Skip to content

Inspection Record

Changzhou SPL Company, Ltd — FDA 483 Findings

US FDAInspected 2015-07-28Published 2024-01-17 3 findingsMaterial and supplier controlOther quality system

View the regulator's official source The source document is always the basis for judgement.

Findings

1Material and supplier control

Control of material flow in the processing area was in adequate in that waste (b )(4) was carted through a door to the outside in the processing area and not provided for by the material flow written procedure .

2Other quality system

There is no report or data to show that leachables for the ( b)(4) bags used to hold Heparin Sodium USP lot, have been evaluated.

3Other quality system

The outer foil bags containing Heparin Sodium USP lot ( b)(4) manufactured and held since 5/25/07, are not labeled.

A record as of the US FDA document published on 2024-01-17. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Changzhou SPL Company, Ltd company profile — full historyAll US FDA findings US FDA documents, 2024 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.